WHAT IS CLAIMED IS:

1. At least one CNGH0005 nucleic acid, comprising at least one polynucleotide comprising or complementary to the all of the contiguous nucleic acids of at least one of SEQ ID NO:3 or 5, or at least one of 424-441 or 2138-2425 of SEQ ID NO:1.

2. At least one CNGH0005 nucleic acid according to claim 1, further comprising 1-111 of SEQ ID NO:1.

3. At least one CNGH0005 nucleic acid according to claim 1, further comprising 112-423 of SEQ ID NO:1.

4. At least one CNGH0005 nucleic acid, comprising at least one polynucleotide comprising or complementary to the all of the contiguous nucleic acids of at least one of SEQ ID NO:5 or 2138-2425 of SEQ ID NO:1, further comprising 533-640 of SEQ ID NO:1.

5. At least one CNGH0005 nucleic acid, comprising at least one polynucleotide comprising or complementary to the all of the contiguous nucleic acids of at least one of SEQ ID NO:5 or 2138-2425 of SEQ ID NO:1, further comprising 641-847 of SEQ ID NO:1.

6. At least one CNGH0005 nucleic acid, comprising at least one polynucleotide comprising or complementary to the all of the contiguous nucleic acids of at least one of SEQ ID NO:6 or 8.

7. At least one CNGH0005 nucleic acid, comprising at least one polynucleotide comprising or complementary to at least 45 contiguous nucleotides of at least one nucleic acid according to any one of claim 1-6.

8. At least one CNGH0005 nucleic acid, comprising at least one polynucleotide having at least 95-99% identity to a nucleotide sequence comprising or complementary to all of the contiguous nucleotides of at least one nucleic acid according to any one of claim 1-6.

9. At least one CNGH0005 nucleic acid, comprising at least one polynucleotide having at least 95-99% identity to a nucleotide sequence comprising or complementary to at least 45 of the contiguous nucleotides of at least one nucleic acid according to any one of claim 1-6.

10. At least one CNGH0005 nucleic acid, comprising at least one polynucleotide that hybridizes under stringent conditions to all of the contiguous nucleotides of at least one of SEQ ID NO:2, 4, 9 or 11 or a polynucleotide complementary thereto.

11. At least one CNGH0005 nucleic acid, comprising at least one polynucleotide that hybridizes under stringent conditions to at least 45 contiguous nucleotides of at least one of SEQ ID NO:2, 4, 9 or 11 or a polynucleotide complementary thereto.

12. At least one CNGH0005 nucleic acid, comprising at least one polynucleotide encoding the amino acid sequence of at least one of SEQ ID NO:12-16, or a polynucleotide complementary thereto.

13. At least one CNGH0005 polypeptide, comprising all of the contiguous amino acids of at least one of SEQ ID NO:12-16.

14. At least one CNGH0005 polypeptide, comprising at least 15 contiguous amino acids of at least one of SEQ ID NO:12-16.

15. At least one CNGH0005 polypeptide, comprising at least one polypeptide having at least 90-99% identity to an amino acid sequence comprising all of the contiguous amino acids of at least one of SEQ ID NO:12-16.

16. At least one CNGH0005 polypeptide, comprising at least one polypeptide having at least 90-99% identity to an amino acid sequence comprising at least 15 of the contiguous amino acids of at least one of SEQ ID NO:12-16.

17. At least one CNGH0005 polypeptide, comprising at least one polypeptide encoded by at least one polynucleotide that hybridizes under stringent conditions to all of the contiguous nucleotides of at least one of SEQ ID NO:2, 4, 9 or 11 or a polynucleotide complementary thereto.

18. At least one CNGH0005 polypeptide, comprising at least one polypeptide encoded by at least one polynucleotide that hybridizes under stringent conditions to at least 45 of the contiguous nucleotides of at least one of SEQ ID NO:2, 4, 9 or 11 or a polynucleotide complementary thereto.

19. At least one CNGH0005 polypeptide, comprising at least one domain or portion selected from 21-123, 30-44, 89-91, 91-98, 105-108, 143-146 of SEQ ID NO:14, 21-123, 30-44, 89-91, 91-98, 105-108, 289-292, 377-401, 389-402, 420-675, 500-522, 543-558 of SEQ ID NO:15, or 21-123, 30-44, 89-91, 91-98, 105-108, 182-185, 206-209 of SEQ ID NO:16.

20. At least one CNGH0005 polypeptide, comprising at least one domain of at least one of SEQ ID NO:12-16.

21. A CNGH0005 nucleic acid or CNGH0005 polypeptide according to any of claims 1-20, wherein said polypeptide has at least one activity of at least one CNGH0005 polypeptide.

22. A CNGH0005 antibody, comprising a monoclonal or polyclonal antibody, fusion protein, or fragment thereof, that specifically binds at least one CNGH0005 polypeptide according to any of claims 1-20.

23. A CNGH0005 nucleic acid encoding at least one CNGH0005 polypeptide or CNGH0005 antibody according to any of claims 1-22.

24. A CNGH0005 vector comprising at least one isolated nucleic acid according to any of claims 1-12 or encoding, or complementary to such nucleic acid encoding, a CNGH0005 according to any of claims 13-20.

25. A CNGH0005 host cell comprising an isolated nucleic acid according to claim 23.

26. A CNGH0005 host cell according to claim 25, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, NSO, DG44 CHO, CHO K1, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

27. A method for producing at least one CNGH0005 polypeptide or CNGH0005 antibody, comprising translating a nucleic acid according to claim 22 under conditions *in vitro*, *in vivo* or *in situ*, such that the CNGH0005 polypeptide is expressed in detectable or recoverable amounts.

28. A composition comprising at least one CNGH0005 nucleic acid, CNGH0005 polypeptide, or CNGH0005 antibody according to any of claims 1-22.

29. A composition according to claim 28, wherein said composition further comprises at least one pharmaceutically acceptable carrier or diluent.

30. A composition according to claim 28, further comprising at least one composition comprising an therapeutically effective amount of at least one compound, composition or polypeptide selected from at least one of a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplactic, an immunomodulation drug, an opthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, or a cytokine antagonist.

31. A composition according to claim 28, in a form of at least one selected from a liquid, gas, or dry, solution, mixture, suspension, emulsion or colloid, a lyophilized preparation, a powder.

32. A method for diagnosing or treating a CNGH0005 related condition in a cell, tissue, organ or animal, comprising

(a) contacting or administering a composition comprising an effective amount of at least one

CNGH0005 nucleic acid, polypeptide or antibody according to any of claims 1-22, with, or to, said cell, tissue, organ or animal.

33. A method according to claim 32, wherein said effective amount is 0.001-50 mg of CNGH0005 antibody; 0.000001-500 mg of said CNGH0005 polypeptide; or 0.0001-100μg of said CNGH0005 nucleic acid per kilogram of said cells, tissue, organ or animal.

34. A method according to claim 32, wherein said contacting or said administrating is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

35. A method according to claim 32, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or polypeptide selected from at least one of a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplactic, an immunomodulation drug, an opthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, or a cytokine antagonist.

36. A device, comprising at least one isolated CNGH0005 polypeptide, antibody or nucleic acid according to any of claims 1-22, wherein said device is suitable for contacting or administerting said at least one of said CNGH0005 polypeptide, antibody or nucleic acid, by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

37. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated CNGH0005 polypeptide, antibody or nucleic acid according to any of claims 1-22.

38. The article of manufacture of claim 37, wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system.

39. A method for producing at least one isolated CNGH0005 polypeptide, antibody or nucleic acid according to any of claims 1-22, comprising providing at least one host cell, transgenic animal, transgenic plant, plant cell capable of expressing in detectable or recoverable amounts said polypeptide, antibody or nucleic acid.

40. At least one CNGH0005 polypeptide, antibody or nucleic acid, produced by a method according to claim 39.